top of page
Profile
Join date: Aug 21, 2020
Posts (37)
Dec 16, 2025 ∙ 2 min
Resoundant’s Magnetic Resonance Elastography Accepted into FDA Biomarker Qualification Program as a Reasonably Likely Surrogate Endpoint in MASH Trials
Rochester, MN — December 16, 2025 — Resoundant, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Letter of Intent into the FDA’s Biomarker Qualification Program (BQP) for Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE) in clinical trials for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2–F3). ...
247
3
Jul 31, 2024 ∙ 3 min
Resoundant Appoints Kay Pepin, PhD, as Chief Operating Officer
Rochester, MN – July 30, 2024 – Resoundant, Inc., a leader in the development and implementation of advanced magnetic resonance...
231
1
Mar 15, 2024 ∙ 3 min
Resoundant Applauds FDA Approval of Resmetirom: A Milestone for MASLD and MASH Patients
Rochester, MN – Resoundant, a Mayo Clinic company and the developer of Magnetic Resonance Elastography (MRE), is thrilled to announce the...
285
4
Resoundant
Admin
More actions
bottom of page